Resource News

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Arch Biopartners Announces Positive Results of Dose Escalation Human Trial for LSALT Peptide

Today, ARCH Biopartners Inc., ("ARCH" or the "Company") (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company focused on the development of novel therapeutics targeting organ inflammation, announced that it has safely increased the maximum daily dose of LSALT peptide to 20 mg per day in healthy, normal volunteers in a recently completed human trial in Australia.

LSALT peptide is the Company's lead drug candidate for treating inflammation in the lungs, liver and kidneys and Arch intends to use the new maximum dose in designing a Phase II trial targeting cardiac surgery-associated acute kidney injury (CS-AKI). The new safety data will be included in an Investigational New Drug Application to the U.S. FDA, to be submitted in relation to the CS-AKI trial in due course.

Prior to this dose escalation trial, LSALT peptide was administered at a maximum of 5mg once daily, for up to 14 days, in hospitalized COVID-19 patients during a Phase II trial targeting inflammation in the lungs.

Dose Escalation Trial

The dose escalation human trial was performed at the Alfred Hospital in Melbourne, Australia. The trial was a double-blind, placebo-controlled, randomized, single and multiple ascending dose study to evaluate the safety and pharmacokinetic profile of LSALT peptide. Sixteen healthy, normal volunteers participated, receiving either LSALT peptide or a placebo, and were divided into two groups.

Six participants in each group received a daily dosing of LSALT peptide for one day followed by three consecutive days of dosing. Two people per group received a placebo with the same dosing schedule. In the first group, six people received a once daily, 10 mg intravenous (IV) dose of LSALT peptide. In the second group, six volunteers received a 10 mg IV dose of LSALT peptide twice a day, approximately every 12 hours.

In both groups, LSALT peptide met the primary endpoints of safety and tolerability.

LSALT Peptide Drug Product Manufacturing Update

During the last few months, Arch has continued to advance the production of new supply of LSALT peptide to be used in non-Covid human trials. The production of approximately 10,000 LSALT peptide drug product vials has recently been completed. The new vials are undergoing quality control and quality assurance procedures at the Company's third-party manufacturing facility in Toronto, Canada. The drug product vials contain approximately 5mg of LSALT peptide and are expected to be released to Arch in May 2023.

About Arch Biopartners

Arch Biopartners Inc. is a clinical stage company focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact. Arch Biopartners is developing a pipeline of new drug candidates that inhibit inflammation in the lungs, kidneys and liver via the dipeptidase-1 (DPEP-1) pathway, relevant for multiple medical indications.

For more information on Arch Biopartner's science and technologies, please visit:

For investor information and other public documents the company has also filed on SEDAR, please visit

The Company has 62,398,825 common shares outstanding.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable Canadian securities laws regarding expectations of our future performance, liquidity and capital resources, as well as the ongoing clinical development of our drug candidates targeting the dipeptidase-1 (DPEP-1) pathway, including the outcome of our clinical trials relating to LSALT Peptide (Metablok), the successful commercialization and marketing of our drug candidates, whether we will receive, and the timing and costs of obtaining, regulatory approvals in Canada, the United States, Europe and other countries, our ability to raise capital to fund our business plans, the efficacy of our drug candidates compared to the drug candidates developed by our competitors, our ability to retain and attract key management personnel, and the breadth of, and our ability to protect, our intellectual property portfolio. These statements are based on management's current expectations and beliefs, including certain factors and assumptions, as described in our most recent annual audited financial statements and related management discussion and analysis under the heading "Business Risks and Uncertainties". As a result of these risks and uncertainties, or other unknown risks and uncertainties, our actual results may differ materially from those contained in any forward-looking statements. The words "believe", "may", "plan", "will", "estimate", "continue", "anticipate", "intend", "expect" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We undertake no obligation to update forward-looking statements, except as required by law. Additional information relating to Arch Biopartners Inc., including our most recent annual audited financial statements, is available by accessing the Canadian Securities Administrators' System for Electronic Document Analysis and Retrieval ("SEDAR") website at .

The science and medical contents of this release have been approved by the Company's Chief Science Officer.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release .

For more information, please contact: Richard Muruve Chief Executive Officer Arch Biopartners, Inc. 647-428-7031 

Primary Logo

News Provided by GlobeNewswire via QuoteMedia

The Conversation (0)
XTANDI®  plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

XTANDI® plus Leuprolide Reduced the Risk of Metastasis by 58% in Non-Metastatic Hormone-Sensitive Prostate Cancer versus Placebo plus Leuprolide

Data from Phase 3 EMBARK trial to be presented as a plenary session during the 2023 American Urological Association Annual Meeting

Results show the potential for XTANDI to add to the standard of care in prostate cancer, if approved

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less



  • A massive sulphide interval grading 2.57% nickel (Ni), 1.61% copper (Cu) and 2.35 g/t Total Precious Metals (TPM) over 3.84 m was intersected down-dip of semi-massive to massive sulphide mineralization drilled in 2021 ( see Photo 1 for core sample and Table 1 for drill intersection details) .
  • Significant disseminated + semi-massive sulphide intervals grading 0.29 to 0.67% Ni, 0.08 to 0.43% Cu and 0.43 to 1.64 g/t TPM over 6.25 to 78.95 m intervals in 7 holes ( see Table 1 for details).
  • Geophysics results show untested conductivity down-dip and along strike of current drilling.
  • Near surface massive to disseminated sulphide mineralization at depths of 7- 170 m .

Nickel Creek Platinum Corp. (TSX: NCP) (OTCQB: NCPCF) ("Nickel Creek" or the "Company") is pleased to announce the results from its 2022 drilling and geophysics program on the Arch Target conducted during the period of July- October 2022 in Yukon, Canada . The timing of the release of these results was largely impacted by the unprecedented volume of samples from exploration projects throughout Yukon submitted to the ALS preparation lab in Whitehorse .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Arch Resources to Announce First Quarter 2023 Results on April 27

Arch Resources to Announce First Quarter 2023 Results on April 27

ARCH Resources, Inc. (NYSE: ARCH) will discuss its first quarter 2023 financial results in an investor conference call on Thursday, April 27, 2023 at 10:00 a.m. Eastern time .

Arch Resources Logo (PRNewsfoto/Arch Resources, Inc.)

Interested participants may access the conference call by dialing 877-870-4263 approximately five to 10 minutes prior to the start time.  For participants calling from an overseas location, please dial +1 412-317-0790.  No passcode is needed.  The call will also be webcast and will be accessible via the "investor" section of the Arch website at .  Following the live event, a replay and an audio download will be available on the site.

Arch's first quarter 2023 earnings release will be distributed via PR Newswire before the market opens on April 27 and will be posted to the company's website at that time.

Arch Resources is a premier producer of high-quality metallurgical products for the global steel industry.  The company operates large, modern and highly efficient mines that consistently set the industry standard for both mine safety and environmental stewardship.

Cision View original content to download multimedia:

SOURCE Arch Resources, Inc.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
  MOAB Minerals

Moab Acquires Initial ~15% Equity Interest In Highly Prospective Ghanian Lithium Projects

Moab Minerals Limited (ASX: MOM) (Moab or the Company) is pleased to announce that the Company has acquired an initial 14.64% interest in CAA Mining Limited (CAA Mining), an exploration and development company focused on lithium and gold exploration in Ghana, Africa.

Keep reading...Show less
  Black Rock Mining Limited

Black Rock Mining Limited (ASX: BKT) – Trading Halt


The securities of Black Rock Mining Limited (‘BKT’) will be placed in trading halt at the request of BKT, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Tuesday, 13 June 2023 or when the announcement is released to the market.

Keep reading...Show less
Marquee Resources

MQR And Mineral Resources (ASX:MIN) Agree To Accelerate Farm-In At WSP

Marquee Resources Limited (“Marquee” or “Company”) (ASX:MQR) is pleased to announce that it has agreed to accelerate the Farm-In agreement with Mineral Resources Limited (ASX:MIN) (MinRes) at the West Spargoville Project (“WSP” or “Project”).

Keep reading...Show less
Building Western Australia’s Next Gold Miner

Building Western Australia’s Next Gold Miner

Investor Presentation - June 2023

Brightstar Resources Limited(ASX:BTR) (Brightstar) is pleased to present its investor presentation.

Keep reading...Show less
Belararox Limited

Environmental Impact Assessments Requested For TMT Project Completed and Lodged

Belararox Ltd (ASX: BRX)(Belararox or the Company) an advanced mineral explorer focused on high-value clean energy metals, is pleased to announce the Environmental Impact Assessment Applications (“EIAs”) to permit exploration activities at the Company’s TMT Project in Argentina have been completed and submitted to the San Juan Mines Department.

Keep reading...Show less
forest fire

Wildfires Interrupt Mining Operations in Quebec

A wildfire crisis in Quebec has halted the operations of some mining corporations in the eastern province.

Nearly 15 mining companies have stopped all operations in the province due to over 150 forest fires engulfing several areas of Quebec, a nearly C$4 billion mining investment space in Canada.

"We're following all of this from hour to hour, obviously," Premier Francois Legault told the media on Tuesday (June 6). "If we look at the situation in Quebec as a whole, there are several places where it is still worrying."

Per a Reuters factbox, 14 companies have all stopped their day-to-day mining operations, dealing a heavy blow to Canada’s vast mining space.

Keep reading...Show less

Latest Press Releases

Related News